Background: The active-targeted drug delivery systems had attracted more and more attention to efficiently overcome multidrug resistance (MDR) in cancer treatments. The aim of the work was to develop a multifunctional nano-structured liposomal system for co-delivery of doxorubicin hydrochloride (DOX) and celecoxib (CEL) to overcome doxorubicin resistance in breast cancer. Methods: A functional hybrid peptide (MTS-R8H3) with unique cellular penetrability, endo-lysosomal escape and mitochondrial targeting ability was successfully synthesized using solid phase synthesis technology. The peptide modified targeted liposomes (DOX/CEL-MTS-R8H3 lipo) for co-delivery of DOX and CEL were formulated to overcome the chemoresistance in MCF/ADR cells. Results: DOX/CEL-MTS-R8H3 lipo showed nanosized shape and displayed high stability for one month. The cytotoxicity effect of the co-delivery of DOX and CEL through peptide modified liposomes had remarkable treatment efficacy on killing MCF/ADR cells. Targeted liposome exhibited greater cellular entry ability about 5.72-fold stronger than DOX solution. Moreover, as compared with unmodified liposomes, the presence of MTS-R8H3 peptide entity on liposome surface enhanced the mitochondrial-targeting ability and achieved effective reactive oxygen species (ROS) production with significant inhibition of P-gp efflux activity. Conclusion: The study suggested that the DOX/CEL-MTS-R8H3 lipo is a promising strategy for overcoming drug resistance in breast cancer treatments with high targeting inhibition efficiency.
Oral liposome drug delivery system has gained attention due to their potential to improve patient compliance, enhance the bioavailability of encapsulated poorly soluble drugs, and protect drugs from gastrointestinal degradation. Liposomes structurally mimic the human cell membrane, and so are biocompatible and facilitate interactions with cell membranes. However, liposome drug delivery remains inherently challenging due to limitations such as physicochemical instability, limited permeability across GI barriers, and manufacturing scalability constraints. This review first summarizes the current innovative oral liposome products such as Meriva®, Lipicur, and silymarin liposomes. This is followed by a comprehensive overview of the biological barriers for liposome absorption. The report further reviews current understanding the mechanisms for liposomes to cross the GI track and enter the bloodstream, including cellular uptake, transepithelial transport, and lymphatic transport. Formulation strategies to improve absorption such as lipid composition, surface modification techniques such as PEGylation and chitosan are discussed. Understanding these properties is essential for enhancing transepithelial transport efficiency and designing effective oral liposome delivery systems. Finally, the recent development in manufacturing scalability is also covered. Owing to their favorable properties, oral liposome delivery systems remain an active area for innovations in expanding their applications. It is anticipated that demand for oral liposomal drug‑delivery systems will continue to grow, driven by the rising prevalence of chronic diseases that require long‑term therapeutic management.